ALung Receives CE Mark for New Hemolung XG4 Cartridge and Catheter Kits
The new Hemolung XG4 Cartridge and Catheter Kits further simplify initiation of Respiratory Dialysis®.
Pittsburgh, PA (June 18, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, today announced that it has received CE mark approval for its next generation Hemolung XG4 Cartridge and Catheter Kits. The devices are used as part of the Hemolung Respiratory Assist System to provide Respiratory Dialysis®, a minimally invasive extracorporeal CO2 removal therapy, as an alternative or supplement to mechanical ventilation for patients suffering from acute respiratory failure.
The Hemolung XG4 Cartridge Kit features a fully pre-connected circuit which makes initiating Hemolung therapy even faster and safer than before. All tubing connections have been made in the factory. This ensures that the circuit is correctly and securely assembled, and speeds the initiation of Hemolung therapy by eliminating several steps from the setup process. Additionally, the new kits are packaged in sterile plastic trays which are easy to handle at the bedside. In the Hemolung Catheter Kit, all insertion accessories have been packaged with the catheter in one tray to improve usability under sterile conditions.
ALung’s approach to device development has always been to make Respiratory Dialysis safe, simple, and effective. “These new kits were developed at the request of our growing user base who identified pre-connected tubing as its most desired feature,” said Peter DeComo, ALung Chairman and CEO. “This update is a major step forward in making Hemolung therapy even easier to implement, and we are pleased to make it available to our customers.”
ALung will showcase the Hemolung XG4 kits at the 6th International Congress on ECMO in Paris on June 25-26, 2015. The new kits will be available in select European markets in July 2015.
About ALung Technologies
ALung Technologies, Inc. is a privately-held Pittsburgh-based developer and manufacturer of innovative lung assist devices. Founded in 1997 as a spin-out of the University of Pittsburgh, ALung has developed the Hemolung RAS as a dialysis-like alternative or supplement to mechanical ventilation. ALung is backed by individual investors and venture firms including Allos Ventures, Birchmere Ventures and West Capital Advisors, LLC.
For more information about ALung and the Hemolung RAS, visit www.alung.com.
This press release may contain forward-looking statements, which, if not based on historical facts, involve current assumptions and forecasts as well as risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events that could cause results to differ include failure to meet ongoing developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with regulatory approval processes, adverse changes to reimbursement for the Company’s products/services, and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time, but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.
Vice President of Marketing
ALung Technologies, Inc.
+1-412-697-3370 ext. 208
Hemolung XG4 Brochure (PDF)